FKFadi Kharouf

Fadi Kharouf

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Fadi Kharouf has a total of 127 co-authors. Here are the top co-authors by number of shared publications:

  • Dafna D. Gladman

    Division of Rheumatology, University of Toronto, Toronto, Ontario, Canada

    22 shared publications
  • Pankti Mehta

    University of Toronto Lupus Clinic, Division of Rheumatology, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network , Toronto, ON

    19 shared publications
  • Shangyi Gao

    University Health Network

    16 shared publications
  • Virginia Carrizo Abarza

    Division of Rheumatology, Toronto Western Hospital, Schroeder Arthritis Institute; 399 Bathurst St, Toronto, Ontario, Canada M5T 2S6

    14 shared publications
  • Vinod Chandran

    Schroeder Arthritis Institute, University Health Network Gladman Krembil Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases Toronto, Ontario

    13 shared publications
  • Daniel Pereira

    University Health Network

    10 shared publications

Latest Publications

  • Antimalarial exposure and renal histopathologic findings in LN

    by Fadi Kharouf, Pankti Mehta, Qixuan Li, Dafna D Gladman, Laura P Whittall Garcia, Zahi Touma

    Objectives: This study aimed to evaluate the association between antimalarial exposure and renal histopathologic findings at kidney biopsy in patients with LN. Methods: This study was conducted within the University of Toronto Lupus Clinic cohort. To ensure adequate assessment of antimalarial exposure, patients were included if they underwent a kidney biopsy at least 3 months after clinic entry. The kidney biopsy served as the index time point (baseline) for the analysis and corresponded to the clinic visit immediately preceding the biopsy. Antimalarial exposure was defined as use during ≥2 consecutive clinic visits prior to biopsy. Sensitivity analyses evaluated longer durations of continuous antimalarial exposure (≥6 months and ≥1 year). Histopathologic outcomes included proliferative vs non-proliferative LN class, NIH activity index (AI), NIH chronicity index (CI) and interstitial fibrosis and tubular atrophy (IFTA) score. Associations were evaluated using logistic and linear regression models adjusted for demographic, clinical and treatment covariates. Results: The study included 165 patients with biopsy-proven LN (median age 35.3 years; 84.2% female; median disease duration 6.2 years), of whom 50.3% were on antimalarial therapy at baseline. In the adjusted multivariable analyses, antimalarial exposure was not associated with detectable differences in proliferative LN, NIH AI, NIH CI or IFTA score. Sensitivity analyses requiring ≥6 months and ≥1 year of continuous antimalarial exposure yielded similar findings. Conclusions: Antimalarial exposure was not associated with detectable differences in renal histopathologic findings at biopsy. These findings should be interpreted within the limitations of the study design and sample size.

  • Open Access

    Methods for ascertainment and categorization of race and ethnicity for clinical research: an overview of reviews

    by Teresa Semalulu, Melanie Anderson, Zayd Schafer, Fadi Kharouf, Emma Neary, Azza Eissa, Shahad Al-Matar, Sadeem AlFraih, Virginia Carrizo Abarza, Abimbola K. Saka, et al.

  • Repeat biopsy in membranous lupus nephritis: extending the lens beyond light microscopy

    by Hagit Peleg, Dafna D. Gladman, Laura P. Whittall Garcia, Zahi Touma, Fadi Kharouf

  • Open Access

    Factors associated with the occurrence, resolution, and recurrence of tender psoriatic dactylitis: Results from a longitudinal cohort study

    by Fadi Kharouf, Pankti Mehta, Virginia Carrizo Abarza, Shangyi Gao, Daniel Pereira, Vinod Chandran, Dafna D. Gladman, Denis Poddubnyy

    Background: Tender (acute) dactylitis is a hallmark manifestation of psoriatic arthritis (PsA), yet longitudinal data on its clinical course and management remain limited. Objectives: We aimed to investigate the clinical factors associated with tender psoriatic dactylitis and examine the associations of different treatment modalities with its occurrence, resolution, and recurrence. Design: Retrospective longitudinal cohort study based on prospectively collected data. Methods: We included patients with PsA from a prospective observational cohort. We used univariable and multivariable generalized estimating equations (GEE), adjusted for calendar decade, to examine clinical factors associated with tender dactylitis. Additionally, we employed univariable and multivariable parametric survival models, adjusted for calendar decade and accounting for interval-censored data, to investigate factors influencing the time to resolution and recurrence of tender dactylitis. Results: Of the 1725 patients included in this study, 639 (37.0%) had at least one episode of tender dactylitis over a median follow-up of 8.9 years [2.4, 16.5]. In multivariable analyses, tender dactylitis was significantly associated with male sex (odds ratio [OR] 3.07, 95% confidence interval [CI] 1.30–7.24) and higher cDAPSA score (OR 1.05, 95% CI 1.03–1.07). In contrast, biologic or targeted synthetic DMARD (b/tsDMARDs) use was inversely associated (OR 0.29, 95% CI 0.13–0.64). Importantly, b/tsDMARD use for managing tender dactylitis was associated with more rapid resolution (HR 1.52, 95% CI 1.04–2.21) and longer time to recurrence (HR 0.51, 95% CI 0.27–0.97), whereas glucocorticoid injections and conventional synthetic DMARDs showed no significant association. Conclusion: Tender dactylitis is common in PsA and is associated with a more severe disease phenotype. In this longitudinal observational cohort, b/tsDMARD use was associated with a lower occurrence of tender dactylitis and more favorable resolution and recurrence outcomes; however, residual confounding by indication cannot be excluded.

  • Open Access

    Impact of depression and anxiety on the components of minimal disease activity (MDA) in patients with psoriatic arthritis

    by Virginia Carrizo Abarza, Pankti Mehta, Fadi Kharouf, Shangyi Gao, Richard J. Cook, Denis Poddubnyy, Dafna D. Gladman, Vinod Chandran

    Background: We have previously demonstrated that the presence of depression/anxiety reduces the probability of achieving sustained Minimal Disease Activity (MDA) in patients with psoriatic arthritis (PsA). Objective: We now aimed to investigate whether the presence of depression/anxiety affects the likelihood of achieving components of MDA in patients with PsA. Design: Observational cohort study using longitudinal data from a prospective PsA cohort. Methods: We included PsA patients satisfying classification criteria, prospectively followed from 2008 to 2024. We defined the presence of depression/anxiety by one of three criteria 1 a score of ≤38 on the SF-36 Mental Component Summary score, 2a score of ≤56 on the SF-36 Mental Health domain, or 3 a rheumatologist’s report of a diagnosis or treatment for depression/anxiety. Generalized Estimating Equations were utilized to evaluate the association between depression/anxiety and being in a state of MDA, as well as each of the seven MDA components. Results: Among 1,130 PsA patients studied, 659 patients (58.3%) met at least one definition of depression/anxiety. The presence of depression/anxiety was associated with a 63% lower likelihood of achieving MDA. Patients with depression/anxiety were significantly less likely to 6 of the 7 MDA criteria, including tender joint count ≤1, swollen joint count ≤1, tender entheseal points ≤1, pain visual analogue scale (VAS) ≤15, global disease activity VAS ≤20, and HAQ score ≤0.5. No association was found between depression/anxiety and achieving PASI≤1. Conclusion: In PsA patients, the presence of depression/anxiety reduces the odds of achieving all criteria of MDA except PASI.

  • Characterizing arthritis subtypes in lupus: prevalence, clinical features and role of type I interferon signatures

    by Pankti Mehta, Fadi Kharouf, Virginia Carrizo-Abarza, Joan Wither, Milin Patel, Qixuan Li, Dafna D Gladman, Laura P Whittall Garcia, Zahi Touma

    Objectives: Arthritis is a common manifestation of systemic lupus erythematosus (SLE). We examined the prevalence and associations of arthritis subtypes in SLE, focusing on associations with type I interferon (IFN) scores. Methods: In this observational cohort study at the University of Toronto Lupus Clinic (July 1970–August 2024), arthritis was defined clinically as non-deforming arthritis (NDA), Jaccoud’s arthropathy (JA) and arthritis with clinically irreducible deformities (CIDA). Univariable and multivariable (MV) logistic regression was used to assess associations with arthritis subtypes with NDA as reference in the prevalent cohort and subgroup with available IFN scores (reported as high/low). Results: Among 2264 patients, 1248 (55.1%) had arthritis: 908 (72.8%) had NDA, 239 (19.2%) JA, and 101 (8.1%) CIDA. In the multivariable logistic regression analysis, JA was associated with longer disease duration (odds ratio [OR] 1.05 [95% CI: 1.03, 1.08]) and female sex (2.06 [1.11, 3.83]) whereas CIDA was associated with neurological involvement (1.79 [1.13, 2.84]), anti-Ro antibodies (1.71 [1.01, 2.90]), higher adjusted mean joint count (1.09 [1.03, 1.77]) and lower adjusted mean SLEDAI-2K over follow-up (0.89 [0.81, 0.98]) compared with NDA. In patients with available IFN scores (n = 475), CIDA was associated with a low IFN signature in unadjusted analysis, whereas both JA and NDA had a high IFN signature. Conclusion: Distinct clinical and serological patterns differentiate JA and CIDA, suggesting unique underlying mechanisms of deforming arthritis in SLE. Both NDA and JA exhibited a high IFN signature, while CIDA showed a higher joint burden, lower disease activity and lower IFN signature relative to NDA.


  • Open Access

    Radiographic Sacroiliitis Progression in Psoriatic Arthritis

    by Virginia Carrizo Abarza, Pankti Mehta, Fadi Kharouf, Shangyi Gao, Richard J Cook, Dafna D Gladman, Vinod Chandran, Denis Poddubnyy

    Objective: To assess radiographic sacroiliitis progression in psoriatic arthritis (PsA) and factors associated with it. Methods: We analyzed a prospective PsA cohort (1978–2025). Pelvic radiographs were obtained biannually. Change (Δ) in the Sacroiliitis Sum Score (SSS, 0–8; left+right modified New York–mNY—grades) was the primary outcome, while patients with SSS = 8 at baseline were excluded from the analyses. Linear mixed-effects models assessed factors associated with ΔSSS over successive clinic visits. As a secondary outcome, time to incident mNY sacroiliitis was evaluated with Cox regression. Results: Among 1,554 eligible patients (median follow-up 6.00 years), 475/1,056 (45%) showed progression in SSS by at least 1 grade. In univariable analyses, male sex, 66-joint swollen count, PASI, nail disease, syndesmophytes, abnormal ESR/CRP and higher DAPSA were associated with progression, while older age and longer PsA duration were associated with less progression. Biologic/targeted synthetic (b/ts) DMARD exposure and follow-up in the post-2011 era were associated with lower progression rates. In multivariable models, older age and b/tsDMARD exposure retained protective associations. Among 831 patients without definite mNY sacroiliitis at baseline and with ≥1 follow-up radiograph, 189 (22.7%) developed definite mNY sacroiliitis. In univariable Cox analysis, nail disease, higher PASI, abnormal ESR/CRP, higher DAPSA, and syndesmophytes were associated with progression, while b/tsDMARD exposure and later eras were associated with lower progression; effects were attenuated after adjustment. Conclusion: Radiographic sacroiliitis progression is common in PsA. Greater inflammatory activity increased risk, whereas b/tsDMARD exposure were protective; progression was lower in the modern treatment era.

  • Open Access

    Body mass index and achievement of minimal disease activity in psoriatic arthritis across different classes of advanced therapy

    by Pankti Mehta, Mu Yang, Fadi Kharouf, Virginia Carrizo Abarza, Shangyi Gao, Richard J Cook, Dafna D Gladman, Vinod Chandran, Denis Poddubnyy

    Objectives: Obesity is a prevalent comorbidity in psoriatic arthritis (PsA). We aimed to evaluate the association between body mass index (BMI) and minimal disease activity (MDA) state in PsA and examine this across different drug classes. Methods: In a longitudinal observational study using the Gladman Krembil PsA Program cohort, patients with available BMI measurement over follow-up were included. Univariable and multivariable (MV) generalized estimating equations and linear mixed models were used to assess associations between BMI and MDA (and its components) over time, adjusting for age, sex, anxiety/depression, fibromyalgia, smoking, treatment type and radiographic damage. Subgroup analyses evaluated this association across six drug classes: TNF-α inhibitors (TNFi), IL-17 inhibitors (IL-17i), IL-12/23 inhibitors (IL-12/23i), IL-23 inhibitors (IL-23i), Janus kinase inhibitors (JAKi) and phosphodiesterase-4 inhibitors (PDE4i). Results: In 1291 patients (mean age 44.7 years, 56% male, mean BMI 28.8 kg/m2), higher BMI was independently associated with lower odds for MDA (MV, odds ratio [OR] 0.97; 95% CI: 0.94, 0.99) along with female sex, older age, smoking, fibromyalgia and radiographic damage. BMI was negatively associated with all MDA components except swollen joint count. Higher BMI at drug initiation was associated with reduced odds for MDA state in TNFi-treated patients excluding infliximab (MV, OR 0.94; 95% CI: 0.92, 0.97), while no significant effect was seen for IL-17i, IL-12/23i, IL-23i or JAKi. Longitudinal BMI assessment similarly showed reduced MDA odds with TNFi (excluding infliximab). Conclusions: High BMI decreases the odds for MDA in PsA, mainly affecting subjective disease measures. This effect is most pronounced in patients treated with TNFi (except infliximab). This underscores the importance of weight management in optimizing treatment response.


  • Open Access

    Comment on: Clinical outcomes in psoriatic arthritis patients with rheumatoid factor positivity: Reply

    by Pankti Mehta, Fadi Kharouf, Virginia Carrizo Abarza, Shangyi Gao, Dafna D Gladman, Vinod Chandran, Denis Poddubnyy

  • Repair of radiographic joint damage in psoriatic arthritis: a cohort study

    by Amir Haddad, Fadi Kharouf, Ker-Ai Lee, Lily Zou, Daniel Pereira, Richard J Cook, Vinod Chandran, Dafna D Gladman

    Objectives: Robust evidence on the repair of radiographic damage in psoriatic arthritis (PsA) is limited. In this study, we determined the frequency of damage repair and identified its predictors. Methods: We performed biennial radiographic assessments of the hands and feet and graded them using the modified Steinbrocker score (mSS). Grades 0 and 1 were combined as a single state. We defined damage repair as a decrease in the joint-level mSS and summarized disease characteristics using descriptive statistics. We defined states based on the mSS and fitted multistate Markov models to estimate transition intensities and assess the impact of prognostic factors on damage repair. Results: We included 674 patients with PsA (54.7% male), with a mean age of 44.4 years (SD 12.8) and a mean disease duration of 6.3 years (SD 8.0) at baseline (clinic entry). Over a total follow-up of 7189.5 person-years, 428 patients (63.4%) developed at least one damaged joint (mSS ≥2) and 127 of them (29.7%) demonstrated evidence of repair in at least one joint. In total, 361 joints demonstrated radiographic improvement. Progression of damage was observed in patients prior to biologic DMARD therapy. Combination of methotrexate and biologic DMARDs was associated with a reduced progression rate for joint damage (RR = 0.48, 95% CI: 0.38–0.62) and an increased rate of damage repair (RR = 1.97, 95% CI: 1.13–3.45). Conclusion: Radiographic improvement consistent with damage repair is not infrequent in PsA. Concomitant treatment with biologic DMARDs and MTX is a predictor of slower radiographic progression and damage repair.